LRMR · Larimar Therapeutics, Inc.

Summary

Larimar Therapeutics reported fourth quarter and full year 2025 financial results, with Q4 net loss of $62.5 million ($0.73 per share) and full year net loss of $165.7 million ($2.27 per share), driven by increased R&D expenses from nomlabofusp manufacturing. Highlights include FDA Breakthrough Therapy Designation for nomlabofusp, BLA submission planned for June 2026, and pro forma cash of $244.5 million extending runway into Q2 2027.